Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab ...

Net loss from continuing operations was $ (20.5) million and $ (38.9) million for the three and nine months ended September 30, 2024, respectively, compared to $ (8.2) million and $ (45.3) million for ...